Benzinga | Jul 14, 2021 07:48AM EDT

SVB Leerink Maintains Outperform on Exact Sciences, Lowers Price Target to $160

SVB Leerink analyst Puneet Souda maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $170 to $160.